Download 213_2014_3807_MOESM1_ESM - Springer Static Content Server

Reference List
1. Addonizio G, Susman VL (1987) ECT as a treatment alternative for patients with
symptoms of neuroleptic malignant syndrome. Journal of Clinical Psychiatry 48:
102-105
2. Adenuga O, Adurty R (2011) A case of neuroleptic malignant syndrome due to
cyclobenzaprine. Chest Conference: October
3. Adityanjee, Singh S, Singh G, Ong S (1988) Spectrum concept of neuroleptic
malignant syndrome. British Journal of Psychiatry 153: 1988
4. Aisen PS, Lawlor BA (1992) Neuroleptic malignant syndrome induced by lowdose haloperidol. American Journal of Psychiatry 149: 844
5. Akpaffiong MJ (1992) Risk factors for neuroleptic malignant syndrome. Journal
of the National Medical Association 84: 800-802
6. Alao AO, Yolles JC, Armenta W, Michaels AT (1999) Neuroleptic malignant
syndrome spectrum: A case report. Journal of Pharmacy Technology 15:
September/October
7. Albucher RC, DeQuardo J, Tandon R (1991) Treatment of catatonia with an
anticholinergic agent. Biological Psychiatry 29: 513-514
8. Aloysi AS, Popeo DM, Kellner CH (2011) Cases of catatonia on an academic
electroconvulsive therapy service: lessons to learn. Journal of ECT 27: 259-261
9. Amdurski S, Radwan M, Levi A, Elizur A (1983) A therapeutic trial of
amantadine in haloperidol-induced malignant neuroleptic syndrome. Current
Therapeutic Research - Clinical and Experimental 33: 1983
10. Angelopoulos EK, Corcondilas M, Kollias CT, Kioulos KT, Bergiannaki JD,
Papadimitriou GN (2010) A case of catatonia successfully treated with
ziprasidone, in a patient with DSM-IV delusional disorder. Journal of Clinical
Psychopharmacology 30: 745-746
11. Ansseau M, Diricq S, Grisar T, Collard J (1980) Biochemical and neuroendocrine
approaches to a malignant syndrome of neuroleptics. Acta Psychiatrica Belgica
80: 600-606
12. Arnaout MS, Antun FP, Ashkar K (2001) Neuroleptic malignant syndrome with
olanzapine associated with severe hypernatremia. Human Psychopharmacology
16: 2001
13. Arnott S, O'Neill D (1993) Case report (1): Neuroleptic malignant syndrome
masked by urinary tract infection. Journal of Drug Development 5: 1993
14. Aruna AS, Murungi JH (2005) Fluphenazine-induced neuroleptic malignant
syndrome in a schizophrenic patient. Annals of Pharmacotherapy 39: 1131-1135
15. Askin R, Herken H, Derman H (2000) Recurrent neuroleptic malignant syndrome:
A case report. International Medical Journal 7: 2000
16. Azhar MZ, Varma SL (1995) Electro-consulsive therapy in neuroleptic malignant
syndrome [2]. European Psychiatry 10: 1995
17. Babington PW, Spiegel DR (2007) Treatment of catatonia with olanzapine and
amantadine. Psychosomatics 48: 534-536
18. Baciewicz AM, Chandra R, Whelan P (2002) Clozapine-associated neuroleptic
malignant syndrome. Annals of Internal Medicine 137: art
19. Baker AS, Suh E, Prudic J (2008) Malignant catatonia: Role of right unilateral
electroconvulsive therapy. Journal of ECT 24: June
20. Baker RW, Chengappa KN (1995) Further study of neuroleptic malignant
syndrome. American Journal of Psychiatry 152: 1831
21. Ball H, de WH, Craig K (2009) An unrecognised case of withdrawal neuroleptic
malignant syndrome: a case report. Medicine, Science & the Law 49: 298-300
22. Basu J (1991) An unusual presentation of neuroleptic malignant syndrome.
Journal of the Indian Medical Association 89: 16
23. Beaubrun MH, Patrick AL (1987) The neuroleptic malignant syndrome (N.M.S.)
in a West Indian of African descent. West Indian Medical Journal 36: 48-50
24. Beauchemin MA, Millaud F, Nguyen KA (2002) A case of neuroleptic malignant
syndrome with clozapine and risperidone. Canadian Journal of Psychiatry - Revue
Canadienne de Psychiatrie 47: 886
25. Becker D, Birger M, Samuel E, Floru S (1988) Myocardial infarction: An unusual
complication of neuroleptic malignant syndrome. Journal of Nervous and Mental
Disease 176: 1988
26. Benazzi F (1999) Clozapine-induced neuroleptic malignant syndrome not
recurring with olanzapine, a structurally and pharmacologically similar
antipsychotic [1]. Human Psychopharmacology 14: 1999
27. Bhugra DK, Low NC (1986) Neuroleptic malignant syndrome. British Journal of
Clinical Practice 40: 445-446
28. Blue MG, Schneider SM, Noro S, Fraley DS (1986) Successful treatment of
neuroleptic malignant syndrome with sodium nitroprusside. Annals of Internal
Medicine 104: 56-57
2
29. Blumlein G (1997) Successful application of amantadine in the treatment of the
malignant neuroleptic syndrome. [German]. Psychiatrische Praxis 24: 1997
30. Bobolakis I (2000) Neuroleptic malignant syndrome after antipsychotic drug
administration during benzodiazepine withdrawal. Journal of Clinical
Psychopharmacology 20: 281-283
31. Bond WS (1984) Detection and management of the neuroleptic malignant
syndrome. Clinical Pharmacy 3: 302-307
32. Bora E, Saffet GA, Akdeniz F, Vahip S (2003) Neuroleptic malignant-like
syndrome induced with low-dose quetiapine treated with electroconvulsive
therapy. European Psychiatry: the Journal of the Association of European
Psychiatrists 18: 323
33. Borovicka MC, Bond LC, Gaughan KM (2006) Ziprasidone- and lithium-induced
neuroleptic malignant syndrome. Annals of Pharmacotherapy 40: 139-142
34. Bort RF (1976) Catatonia, gastric hyperacidity, and fatal aspiration: a preventable
syndrome. American Journal of Psychiatry 133: 446-447
35. Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller HJ (2002) Neuroleptic
malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Pharmacopsychiatry 35: 119-121
36. Bourgeois JA, Babine S, Meyerovich M, Doyle J (2002) A case of neuroleptic
malignant syndrome with quetiapine. Journal of Neuropsychiatry & Clinical
Neurosciences 14: 87
37. Bourgeois JA, Kahn DR (2003) Neuroleptic malignant syndrome following
administration of risperidone and lithium. Journal of Clinical
Psychopharmacology 23: 315-317
38. Boyarsky BK, Fuller M, Early T (1999) Malignant catatonia-induced respiratory
failure with response to ECT. Journal of ECT 15: 232-236
39. Braunig P (1991) 48-hour cycles of alternating catatonic syndromes ('Catatonia
alternans'). [German]. Fortschritte der Neurologie Psychiatrie 59: 1991
40. Braunig P, Kruger S, Hoffler J (1995) Worsening of catatonic symptoms during
neuroleptic therapy. [German]. Nervenarzt 66: 1995
41. Brenner I, Rheuban WJ (1978) The catatonic dilemma. American Journal of
Psychiatry 135: 1242-1243
42. Burger O, Rambach S, Steinberg R (1991) Combination of neuroleptics and
lorazepam in the treatment of catatonic schizophrenia. [German]. TW Neurologie
Psychiatrie 5: 1991
3
43. Burkhard PR, Vingerhoets FJ, Alberque C, Landis T (1999) Olanzapine-induced
neuroleptic malignant syndrome. Archives of General Psychiatry 56: 101-102
44. Burrell MF, Fewster C, Szabadi E, Cashman M (1991) Clozapine-treated NMS.
British Journal of Psychiatry 158: 577
45. Carey SJ, Hall DJ, Jones GA (2002) Grand rounds: Catatonia. Psychiatric Bulletin
26: 2002
46. Casamassima F, Lattanzi L, Perlis RH, Litta A, Fui E, Bonuccelli U, Fricchione
G, Cassano GB (2010) Neuroleptic malignant syndrome: further lessons from a
case report. Psychosomatics 51: 349-354
47. Cassidy EM, O'Brien M, Osman MF, Finucane J, O'Keane V (2001) Lethal
catatonia responding to high-dose olanzapine therapy. Journal of
Psychopharmacology 15: 302-304
48. Castellani S (1985) Catatonia associated with phenylpropanolamine overdose and
fluphenazine treatment: case report. Journal of Clinical Psychiatry 46: 288-289
49. Chakraborty N, Johnston T (2004) Aripiprazole and neuroleptic malignant
syndrome. International Clinical Psychopharmacology 19: 351-353
50. Chang CH, Hsiao YL, Hsu CY, Chen ST (2009) Treatment of catatonia with
olanzapine: a case report. Progress in Neuro-Psychopharmacology & Biological
Psychiatry 33: 1559-1560
51. Chatterjee SK, Sapra ML (1978) Pernicious catatonia. (A report). Medical Journal
Armed Forces India 34: 1978
52. Chen YT, Su KP, Chang JP (2011) Early detection and management of atypical
neuroleptic malignant syndrome secondary to aripiprazole. Schizophrenia
Research 132: 97-98
53. Choi H-D, Kim K-K, Koo B-H (2011) A case of catatonia and neuroleptic
malignant syndrome probably associated with antipsychotic in Korea. Psychiatry
Investigation 8: June
54. Cohen S, Fligner CL, Raisys VA, Luthi R, Dunner DL (1987) A case of
nonneuroleptic malignant syndrome. Journal of Clinical Psychiatry 48: 287-288
55. Connelly MA, Fowler EK (1992) Neuroleptic malignant syndrome. Journal of the
American Board of Family Practice 5: 327-331
56. Cope RV, Gregg EM (1983) Neuroleptic malignant syndrome. British Medical
Journal 286: 1983
4
57. Corallo CE, Ernest D (2007) Atypical neuroleptic malignant syndrome with longterm clozapine. Critical Care & Resuscitation 9: 338-340
58. Cottencin O, Thomas P, Vaiva G, Rascle C, Goudemand M (1999) A case of
agitated catatonia. Pharmacopsychiatry 32: 38-40
59. Cottencin O, Danel T, Goudemand M, Thomas P, Consoli SM (2009) Catatonia
recognition and treatment. Medical Science Monitor 15: CS129-CS131
60. Craddock B, Craddock N (1997) Contractures in neuroleptic malignant syndrome
[3]. American Journal of Psychiatry 154: 1997
61. Cruz FG, Thiagarajan D, Harney JH (1983) Neuroleptic malignant syndrome after
haloperidol therapy. Southern Medical Journal 76: 684-686
62. Dahm JB, Trenckmann U (1991) [Neuroleptic malignant syndrome]. [German].
Medizinische Klinik 86: 601-604
63. DasGupta K, Young A (1991) Clozapine-induced neuroleptic malignant
syndrome. Journal of Clinical Psychiatry 52: 105-107
64. Dassa D, Drai-Moog D, Samuelian JC (2010) Neuroleptic malignant syndrome
with the addition of aripiprazole to clozapine. Progress in NeuroPsychopharmacology & Biological Psychiatry 34: 427-428
65. de LJ, Saiz-Ruiz J, onso-Abolafia A, Pico-Soler E, Munoz-Ruata J, de lS, I (1990)
Neuroleptic-induced catatonia: neuroleptic malignant syndrome? Progress in
Neuro-Psychopharmacology & Biological Psychiatry 14: 129-136
66. Deuschl G, Oepen G, Hermle L, Kindt H (1987) Neuroleptic malignant
syndrome: observations on altered consciousness. Pharmacopsychiatry 20: 168170
67. Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D (1983) Treatment of the
neuroleptic malignant syndrome with bromocriptine. JAMA 250: 484-485
68. Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED (1987) Bromocriptine
treatment of neuroleptic malignant syndrome. Journal of Clinical Psychiatry 48:
1987
69. Diedler J, Mellado P, Veltkamp R (2008) Endovascular cooling in a patient with
neuroleptic malignant syndrome. Journal of the Neurological Sciences 264: 163165
70. Doan RJ, Callaghan WD (2000) Clozapine treatment and neuroleptic malignant
syndrome. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 45:
394-395
5
71. Dorevitch A, Gabbay F (1983) Neuroleptic-associated catatonic reaction. Clinical
Pharmacy 2: 1983
72. Dosani RA (1983) Haloperidol-induced neuroleptic malignant syndrome.
Southern Medical Journal 76: 546
73. Downey GP, Rosenberg M, Caroff S, Beck S, Rosenberg H, Gerber JC, HeimanPatterson TD, Aronson MD (1984) Neuroleptic malignant syndrome. Patient with
unique clinical and physiologic features. American Journal of Medicine 77: 338340
74. Duggal HS (2001) Neuroleptic malignant syndrome precipitated by promethazine
and lorazepam. Australian & New Zealand Journal of Psychiatry 35: 250-251
75. Duggal HS, Gandotra G (2005) Risperidone treatment of periodic catatonia.
Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 50: 241-242
76. Duggal HS (2005) Risperidone treatment of febrile catatonia in first-episode
psychosis. General Hospital Psychiatry 27: 80-81
77. Duke M (1984) Neuroleptic malignant syndrome. Medical Journal of Australia
141: 198-199
78. Edgar J (1999) Droperidol-induced neuroleptic malignant syndrome. Hospital
Medicine (London) 60: 448-449
79. Eles GR, Songer JE, DiPette DJ (1984) Neuroleptic malignant syndrome
complicated by disseminated intravascular coagulation. Archives of Internal
Medicine 144: 1296-1297
80. Elizalde-Sciavolino C, Racco A, Proscia-Lieto T, Kleiner M (1998) Severe
hyponatremia, neuroleptic malignant syndrome, rhabdomyolysis and acute renal
failure: a case report. Mount Sinai Journal of Medicine 65: 284-288
81. Enterman JH, van DD (2011) The curious case of a catatonic patient.
Schizophrenia Bulletin 37: 235-237
82. Evcimen H, ici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM (2007)
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode
psychosis. Journal of Psychiatric Practice 13: 117-119
83. Fekadu A, Bisson JI (2005) Neuroleptic malignant syndrome: diagnostic and
therapeutic dilemmas. Behavioural Neurology 16: 9-13
84. Ferioli V, Manes A, Melloni C, Nanni S, Boncompagni G (2004) Atypical
neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief
treatment with dantrolene. Canadian Journal of Psychiatry - Revue Canadienne de
Psychiatrie 49: 497-498
6
85. Forstl H, Hewer W (1989) Malignant neuroleptic-induced syndrome and lethal
catatonia. [German]. Intensivmedizin und Notfallmedizin 26: 1989
86. Francis A, Divadeenam KM, Bush G, Petrides G (1997) Consistency of
symptoms in recurrent catatonia. Comprehensive Psychiatry 38: 56-60
87. Fraser D, Jibani M (2000) An unexpected and serious complication of treatment
with the atypical antipsychotic drug clozapine. Clinical Nephrology 54: 78-80
88. French K, Eastwood D (2003) Response of catatonic schizophrenia to
amisulpride: a case report. Canadian Journal of Psychiatry - Revue Canadienne de
Psychiatrie 48: 570
89. Fricchione GL, Cassem NH, Hooberman D, Hobson D (1983) Intravenous
lorazepam in neuroleptic-induced catatonia. Journal of Clinical
Psychopharmacology 3: 338-342
90. Gaertner HJ, Horner W, Bartels M (1983) [Catatonic symptoms as a side effect of
neuroleptic treatment]. [German]. Nervenarzt 54: 250-254
91. Gallelli L, Spagnuolo V, Palleria C, De SG, Ferraro M (2009) A case of
neuroleptic malignant syndrome induced by risperidone in a schizophrenic
woman. Current Drug Safety 4: 119-120
92. Ganelin L, Lichtenberg PS, Marcus EL, Munter RG (1996) Suspected neuroleptic
malignant syndrome in a patient receiving clozapine. Annals of Pharmacotherapy
30: 248-250
93. Gangadhar BN, Desai NG, Channabasavanna SM (1984) Amantadine in the
neuroleptic malignant syndrome. Journal of Clinical Psychiatry 45: 526
94. Gervasoni N, Aubry J-M (2008) A catatonic syndrome in a postpartum major
depressive episode with psychotic features. Schweizer Archiv fur Neurologie und
Psychiatrie 159: October
95. Ghaffari N, Dossett E, Lee RH, Aghajanian P (2012) Antipsychotics leading to
neuroleptic malignant syndrome in pregnancy. Obstetrics & Gynecology 119: t-8
96. Gibb WRG, Wedzicha JA, Hoffbrand BI (1986) Recurrent neuroleptic malignant
syndrome and hyponatraemia. Journal of Neurology Neurosurgery and Psychiatry
49: 1986
97. Goates MG, Escobar JI (1992) An apparent neuroleptic malignant syndrome
without extrapyramidal symptoms upon initiation of clozapine therapy: report of a
case and results of a clozapine rechallenge. Journal of Clinical
Psychopharmacology 12: 139-140
7
98. Goekoop JG, Carbaat PA (1982) Treatment of neuroleptic malignant syndrome
with dantrolene. Lancet 2: 49-50
99. Goldwasser HD, Hooper JF (1988) Neuroleptic malignant syndrome. American
Family Physician 38: 1988
100. Goldwasser HD, Hooper JF, Spears NM (1989) Concomitant treatment of
neuroleptic malignant syndrome and psychosis. British Journal of Psychiatry 154:
102-104
101. Gomez-Esteban JC, Barcena J, Forcadas M, Somme J, Agundez M, Tijero B,
Zarranz JJ (2009) Neuroleptic malignant syndrome and serotonin syndrome in a
female patient: a clinicopathologic case. Clinical Neuropharmacology 32: 299300
102. Gonner F, Baumgartner R, Schupbach D, Merlo MC (1999) Neuroleptic
malignant syndrome during low dosed neuroleptic medication in first-episode
psychosis: a case report. Psychopharmacology 144: 416-418
103. Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S (1983)
Neuroleptic malignant syndrome: successful treatment with dantrolene and
bromocriptine. Annals of Neurology 14: 89-90
104. Greedharry D, Bowen R (1993) Lethal catatonia and neuroleptic malignant
syndrome. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 38:
236-237
105. Greenberg LB, Gujavarty K (1985) The neuroleptic malignant syndrome: Review
and report of three cases. Comprehensive Psychiatry 26: 1985
106. Grenier E, Ryan M, Ko E, Fajardo K, John V (2011) Risperidone and lorazepam
concomitant use in clonazepam refractory catatonia: a case report. Journal of
Nervous & Mental Disease 199: 987-988
107. Grey P (1986) Early diagnosis of neuroleptic malignant syndrome. Journal of
Clinical Psychiatry 47: 154
108. Grigg JR (1988) Neuroleptic malignant syndrome and malignant hyperthermia.
American Journal of Psychiatry 145: 1175
109. Grignon S, Brethes JI, Chamberland M, Guimaraes DB (2005) Incipient
neuroleptic malignant syndrome with quetiapine/paroxetine combination
treatment: Atypical presentation and early, successful rechallenge with
olanzapine. International Journal of Psychiatry in Clinical Practice 9: December
110. Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH (1998) Catatonia treated
with transcranial magnetic stimulation. American Journal of Psychiatry 155: 1630
8
111. Grover S, Aggarwal M (2011) Long-term maintenance lorazepam for catatonia: A
case report. General Hospital Psychiatry 33: January-February
112. Grunhaus L, Sancovici S, Rimon R (1979) Neuroleptic malignant syndrome due
to depot fluphenazine. Journal of Clinical Psychiatry 40: 99-100
113. Gupta S, Racaniello AA (2000) Neuroleptic malignant syndrome associated with
amoxapine and lithium in an older adult. Annals of Clinical Psychiatry 12: 107109
114. Guzman CS, Myung VH, Wang YP (2008) Treatment of periodic catatonia with
atypical antipsychotic, olanzapine. Psychiatry & Clinical Neurosciences 62: 482
115. Haggarty JM, Husni M, Peat C, Allain S (1999) Atypical neuroleptic malignant
syndrome? Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 44:
711-712
116. Haisma HJ, Constantinou E, Chinyanga HM (1990) Neuroleptic malignant
syndrome. Central African Journal of Medicine 36: 141-143
117. Hall KL, Taylor WH, Ware MR (2001) Neuroleptic malignant syndrome due to
olanzapine. Psychopharmacology Bulletin 35: 49-54
118. Hamburg P, Weilburg JB, Cassem NH (1986) Relapse of neuroleptic malignant
syndrome with early discontinuation of amantadine therapy. Comprehensive
Psychiatry 27: 1986
119. Han C, Lee SJ, Pae CU (2011) Paliperidone-associated atypical neuroleptic
malignant syndrome: a case report. Progress in Neuro-Psychopharmacology &
Biological Psychiatry 35: 650-651
120. Hanin B, Lerner Y (1993) Neuroleptic malignant syndrome: Neuroleptic
rechallenge after electroconvulsive therapy. Convulsive Therapy 9: 1993
121. Hanson GD, Brown MJ (1973) Waxy flexibility in a postpartum woman - a case
report and review of the catatonic syndrome. Psychiatric Quarterly 47: 1973
122. Harradine PG, Williams SE, Doherty SR (2001) Neuroleptic malignant syndrome:
An underdiagnosed condition. Medical Journal of Australia 174: 04
123. Harris M, Nora L, Tanner CM (1987) Neuroleptic malignant syndrome responsive
to carbidopa/levodopa: support for a dopaminergic pathogenesis. Clinical
Neuropharmacology 10: 186-189
124. Harter C, Obier C, Druschky KF, Eikelmann B (2008) [Malignant neuroleptic
syndrome associated with amisulpride]. [German]. Nervenarzt 79: 86-89
9
125. Hayashi H, Kawakatsu S, Watanabe K, Fukasawa T, Otani K (2002) Neuroleptic
malignant syndrome complicated by massive intestinal bleeding in a patient with
chronic renal failure. Progress in Neuro-Psychopharmacology & Biological
Psychiatry 26: 1225-1227
126. Hayashi H, Aoshima T, Otani K (2006) Malignant catatonia with severe
bronchorrhea and its response to electroconvulsive therapy. Progress in NeuroPsychopharmacology & Biological Psychiatry 30: 310-311
127. Hensel M, Bohler K, Marnitz R, Binder C, von BM (2010) [Intensive care
treatment for neuroleptic malignant syndrome]. [German]. Anasthesiologie,
Intensivmedizin, Notfallmedizin, Schmerztherapie 45: 448-455
128. Hermesh H, Huberman M, Radvan H, Kott E (1984) Single case study. Recurrent
neuroleptic malignant syndrome due to tiapride and haloperidol: The possible role
of D-2 dopamine receptors. Journal of Nervous and Mental Disease 172: 1984
129. Hermesh H, Aizenberg D, Weizman A (1987) A successful electroconvulsive
treatment of neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 75:
237-239
130. Hermle L, Oepen G (1986) [Differential diagnosis of acute life threatening
catatonia and malignant neuroleptic syndrome--a case report]. [German].
Fortschritte der Neurologie-Psychiatrie 54: 189-195
131. Hesslinger B, Walden J, Normann C (2001) Acute and long-term treatment of
catatonia with risperidone. Pharmacopsychiatry 34: 25-26
132. Hickey C, Stewart C, Lippmann S (1999) Olanzapine and NMS. Psychiatric
Services 50: 836-837
133. Hoffman AS, Schwartz HI, Novick RM (1986) Catatonic reaction to accidental
haloperidol overdose: an unrecognized drug abuse risk. Journal of Nervous &
Mental Disease 174: 428-430
134. Hosty G (1992) Neuroleptic malignant syndrome in two sisters. Irish Journal of
Psychological Medicine 9: 1992
135. Hsu WC, Lin ST, Chen CC, Tsang HY, Huang MF (2011) A self-limiting case of
atypical neuroleptic malignant syndrome associated with zotepine. Journal of
Clinical Psychopharmacology 31: 667-669
136. Hudcova J, Schumann R (2006) Electroconvulsive therapy complicated by lifethreatening hyperkalemia in a catatonic patient. General Hospital Psychiatry 28:
440-442
10
137. Hung YY, Yang PS, Huang TL (2006) Clozapine in schizophrenia patients with
recurrent catatonia: report of two cases. Psychiatry & Clinical Neurosciences 60:
256-258
138. Ingraham MR, Joo CJ, Tovin K (1982) The neuroleptic malignant syndrome: a
case report. International Journal of Psychiatry in Medicine 12: 43-47
139. Jessee SS, Anderson GF (1983) ECT in the neuroleptic malignant syndrome: case
report. Journal of Clinical Psychiatry 44: 186-188
140. Johnson GC, Manning DE (1983) Neuroleptic-induced catatonia: case report.
Journal of Clinical Psychiatry 44: 310-312
141. Kang SG, Lee HJ, Lee MS, Kim L, Park JS (2006) Atypical neuroleptic
malignant syndrome associated with aripiprazole. Journal of Clinical
Psychopharmacology 26: 534
142. Karacetin G, Bayar R, Demir T (2012) Successful treatment of benzodiazepineresistant malignant catatonia with electroconvulsive therapy. Journal of
Neuropsychiatry and Clinical Neurosciences 24: 2012
143. Kasantikul D, Kanchananakhin P (1999) Severe catatonia and neuroleptic
malignant syndrome: Report of 3 cases. Journal of the Medical Association of
Thailand 82: 1999
144. Kelly E, Brull SJ (1994) Neuroleptic malignant syndrome and mivacurium: A
safe alternative to succinylcholine? Canadian Journal of Anaesthesia 41: 1994
145. Kemperman CJ (1989) Zuclopenthixol-induced neuroleptic malignant syndrome
at rechallenge and its extrapyramidal effects. British Journal of Psychiatry 154:
562-563
146. Kiyatake I, Yamaji K, Shirato I, Kubota M, Nakayama S, Tomino Y, Koide H
(1991) A case of neuroleptic malignant syndrome with acute renal failure after the
discontinuation of sulpiride and maprotiline. Japanese Journal of Medicine 30:
387-391
147. Kline SS, Mauro LS, Scala-Barnett DM, Zick D (1989) Serotonin syndrome
versus neuroleptic malignant syndrome as a cause of death. Clinical Pharmacy 8:
510-514
148. Knific J, Kogoj A (2008) Amisulpride-induced neuroleptic malignant syndrome.
Acta Neuropsychiatrica 20: April
149. Kocmur M, Vodopivec Z (2006) Reappearance of catatonia. A case report.
Neuroendocrinology Letters 27: 260-262
11
150. Kohen I (2008) Neuroleptic malignant syndrome in a skilled nursing facility
resident. Annals of Long-Term Care 16: September
151. Konig F, Loble M, Wolfersdorf M (1996) [Depressive stupor--malignant
neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult
differential diagnosis]. [German]. Nervenarzt 67: 407-412
152. Kontaxakis VP, Christodoulou GN, Markidis MP, Havaki-Kontaxaki BJ (1988)
Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam.
Acta Psychiatrica Scandinavica 78: 396-398
153. Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA, Katritsis DE, Christodoulou
GN (2003) Neuroleptic Malignant Syndrome after Addition of Paroxetine to
Olanzapine [6]. Journal of Clinical Psychopharmacology 23: December
154. Koponen H, Repo E, Lepola U (1988) Neuroleptic malignant syndrome.
Biological Psychiatry 24: 943-945
155. Korn-Lubetzki I, Gottlieb S (2001) Neuroleptic malignant syndrome with
hypotonia: a diagnostic challenge. European Neurology 46: 50-51
156. Kosehasanogullari SG, Akdede B, Akvardar Y, Akan M, Tunca Z (2007)
Neuroleptic malignant syndrome caused by combination of risperidone and
lithium in a patient with multiple medical comorbidities. Progress in NeuroPsychopharmacology & Biological Psychiatry 31: 1147-1148
157. Kozian R, Lesser K, Peter K (1996) Dysarthric disorders associated with the
neuroleptic malignant syndrome. Pharmacopsychiatry 29: 1996
158. Krahenmann R, Kuchenhoff B, Boker H, Schick M (2010) [Catatonic dilemma in
a schizoaffective patient with combined lithium-risperidone administration].
[German]. Psychiatrische Praxis 37: 306-309
159. Kruger S, Braunig P (2001) Intravenous valproic acid in the treatment of severe
catatonia. Journal of Neuropsychiatry & Clinical Neurosciences 13: 303-304
160. Krull F, Risse A (1986) Neuroleptic malignant syndrome with rhabdomyolysis
and therapy with physostigmine. [German]. Fortschritte der Neurologie
Psychiatrie 54: 1986
161. Krull F, Risse A (1986) Neuroleptic malignant syndrome with rhabdomyolysis
and therapy with physostigmine. [German]. Fortschritte der Neurologie
Psychiatrie 54: 1986
162. Kumagai H, Onoyama K, Washio M, Harada A, Takenaka M, Kobayashi M,
Takeyoshi S (1987) A case of neuroleptic malignant syndrome with acute renal
failure effectively treated with dantrolene. Current Therapeutic Research Clinical and Experimental 42: 1987
12
163. Kunju PA, Bhaskaran R, Nair KR (1990) Neuroleptic malignant syndrome
improved by bromocriptine. Journal of the Association of Physicians of India 38:
358-359
164. Kunz M, Gomes FA, Tramontina JF, Kapczinski F (2007) Late-onset neuroleptic
malignant syndrome in a patient using olanzapine. Journal of Clinical
Psychopharmacology 27: 303-304
165. Kwentus JA, Schulz SC, Hart RP (1984) Tardive dystonia, catatonia, and
electroconvulsive therapy. Journal of Nervous & Mental Disease 172: 171-173
166. Ladds B, Thomas P, Mejia C, Hauser D (2009) Extreme elevation of creatinine
phosphokinase levels in neuroleptic malignant syndrome associated with atypical
antipsychotics. American Journal of Psychiatry 166: 114-115
167. Lal V, Sardana V, Thussu A, Sawhney IMS, Prabhakar S (1997) Cerebellar
degeneration following neuroleptic malignant syndrome. Postgraduate Medical
Journal 73: 1997
168. Lannas PA, Pachar JV (1993) A fatal case of neuroleptic malignant syndrome.
Medicine, Science & the Law 33: 86-88
169. Lappa A, Podesta M, Capelli O, Castagna A, Di PG, Alampi D, Semeraro F
(2002) Successful treatment of a complicated case of neuroleptic malignant
syndrome. Intensive Care Medicine 28: 976-977
170. Lausberg H, Hellweg R (1998) ["Catatonic dilemma". Therapy with lorazepam
and clozapine]. [German]. Nervenarzt 69: 818-822
171. Lavie CJ, Ventura HO, Walker G (1986) Neuroleptic malignant syndrome: three
episodes with different drugs. Southern Medical Journal 79: 1571-1573
172. Lazarus A (1986) Treatment of neuroleptic malignant syndrome with
electroconvulsive therapy. Journal of Nervous and Mental Disease 174: 1986
173. Lee H, Ryan J, Mullett G, Lawlor BA (1994) Neuroleptic malignant syndrome
associated with the use of risperidone, an atypical antipsychotic agent. Human
Psychopharmacology 9: 1994
174. Lee J, Teoh T, Lee TS (2008) Catatonia and psychosis associated with
sibutramine: a case report and pathophysiologic correlation. Journal of
Psychosomatic Research 64: 107-109
175. Lee JW, Robertson S (1997) Clozapine withdrawal catatonia and neuroleptic
malignant syndrome: a case report. Annals of Clinical Psychiatry 9: 165-169
176. Lee JW, Robertson S (1997) Clozapine withdrawal catatonia and neuroleptic
malignant syndrome: a case report. Annals of Clinical Psychiatry 9: 165-169
13
177. Lee TH, Tang LM (1988) Neuroleptic malignant syndrome. Journal of Neurology
235: 324-325
178. Legras A, Hurel D, Dabrowski G, Grenet D, Graveleau P, Loirat P (1988)
Protracted neuroleptic malignant syndrome complicating long-acting neuroleptic
administration. American Journal of Medicine 85: 1988
179. Leigh TH, Lambert MT (1991) A curious case of catatonia. British Journal of
Hospital Medicine 46: 402
180. Leikin JB, Baron S, Engle J, Zell M, Hryhorczuk DO (1988) Treatment of
neuroleptic malignant syndrome with diphenhydramine. Veterinary and Human
Toxicology 30: 1988
181. Lenler-Petersen P, Hansen BD, Hasselstrom L (1990) A rapidly progressing lethal
case of neuroleptic malignant syndrome. Intensive Care Medicine 16: 1990
182. Leung SK (2001) Catatonia and neuroleptic malignant syndrome. Hong Kong
Journal of Psychiatry 11: 2001
183. Levenson JL (1999) Neuroleptic malignant syndrome after the initiation of
olanzapine. Journal of Clinical Psychopharmacology 19: 477-478
184. Levin GM, Lazowick AL, Powell HS (1996) Neuroleptic malignant syndrome
with risperidone. Journal of Clinical Psychopharmacology 16: 192-193
185. Levitt AJ, Midha R, Craven JL (1990) Neuroleptic malignant syndrome with
intravenous haloperidol. Canadian Journal of Psychiatry - Revue Canadienne de
Psychiatrie 35: 789
186. Lew TY, Tollefson G (1983) Chlorpromazine-induced neuroleptic malignant
syndrome and its response to diazepam. Biological Psychiatry 18: 1983
187. Liu PY, Wu PC, Chen CY, Chen YC (2011) Potentiating effect of fluphenazine
decanoate and risperidone on development of neuroleptic malignant syndrome.
General Hospital Psychiatry 33: 84-87
188. Ljubisavljevic V (2002) Lethal catatonia. Australian & New Zealand Journal of
Psychiatry 36: 563-564
189. Looi JC, Cubis JC, Saboisky J (1995) Hyponatremia, convulsions and neuroleptic
malignant syndrome in a male with schizoaffective disorder. Australian & New
Zealand Journal of Psychiatry 29: 683-687
190. Looper KJ, Milroy TM (1997) Catatonia 20 years later. American Journal of
Psychiatry 154: 883
14
191. Loutsch E, Kaiser R, Kalikow K (1984) Electroconvulsive therapy and the
catatonic dilemma. Journal of the American Medical Womens Association 39:
133-134
192. Mahmood T, Warren JP (1989) Neuroleptic malignant syndrome from
chlorpromazine: case report. Journal of the Royal College of General Practitioners
39: 211
193. Mall GD, Hake L, Benjamin AB, Adityanjee A (2008) Catatonia and mild
neuroleptic malignant syndrome after initiation of long-acting injectable
risperidone: case report. Journal of Clinical Psychopharmacology 28: 572-573
194. Malyuk R, Gibson B, Procyshyn RM, Kang N (2002) Olanzapine associated
weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.
International Journal of Geriatric Psychiatry 17: 326-328
195. Maniam T, Jamaluddin J, Kyaw O (1988) Neuroleptic malignant syndrome--a
study of 4 cases. Singapore Medical Journal 29: 293-295
196. Manser TJ, Warner JF (1990) Neuroleptic malignant syndrome associated with
prochlorperazine. Southern Medical Journal 83: 73-74
197. Manto M, Goldman S, Hildebrand J (1996) Cerebellar gait ataxia following
neuroleptic malignant syndrome [1]. Journal of Neurology 243: 1996
198. Margetic B, ukst-Margetic B (2005) Neuroleptic malignant syndrome and
clozapine withdrawal at the same time? Progress in Neuro-Psychopharmacology
& Biological Psychiatry 29: 145-147
199. Markham-Abedi C, McNeely C, de LJ (2007) A case report with ziprasidoneinduced catatonic symptoms. Journal of Neuropsychiatry & Clinical
Neurosciences 19: 476-477
200. Marshall PB, Mellman TA, Nguyen SX (2008) Neuroleptic malignant syndrome
with the addition of aripiprazole to olanzapine. American Journal of Psychiatry
165: 1488-1489
201. Martin ML, Lucid EJ, Walker RW (1985) Neuroleptic malignant syndrome.
Annals of Emergency Medicine 14: 354-358
202. Martius P, Huther R, Zilker T (1996) Malignant neuroleptic syndrome. A case
report. [German]. Nervenarzt 67: May
203. Mashimo K, Kanaya M, Yamauchi T (1995) Electroconvulsive therapy for a
schizophrenic patient in catatonic stupor with joint contracture. Convulsive
Therapy 11: 216-219
15
204. Masters JC, Spitler R (1986) Neuroleptic malignant syndrome. Journal of
Psychosocial Nursing & Mental Health Services 24: 10-16
205. Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K (2005)
Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine.
American Journal of Psychiatry 162: 812
206. Matthes SJ, Cersosimo RJ (1986) Haloperidol induced neuroleptic malignant
syndrome. Clinical Research Practices and Drug Regulatory Affairs 4: 1986
207. May DC, Morris SW, Stewart RM (1983) Neuroleptic malignant syndrome:
Response to dantrolene sodium. Annals of Internal Medicine 98: 1983
208. McCarron MM, Boettger ML, Peck JJ (1982) A case of neuroleptic malignant
syndrome successfully treated with amantadine. Journal of Clinical Psychiatry 43:
381-382
209. McCarthy A, Bourke S, Fahy J, Binchy I, Fitzgerald MX (1988) Fatal recurrence
of neuroleptic malignant syndrome. British Journal of Psychiatry 152: 558-559
210. McDaniel WW, Spiegel DR (2010) Hyponatremia and abnormal ingestion of
water in catatonia. Primary Psychiatry 17: April
211. McDonough CM, Swift G, Managan B, Sheehan JD (2000) Neuroleptic
malignant syndrome: a diagnosis easily missed. Irish Medical Journal 93: 152-154
212. McEvoy JP, Lohr JB (1984) Diazepam for catatonia. American Journal of
Psychiatry 141: 284-285
213. McHugh TP (1992) Neuroleptic malignant syndrome. Journal - South Carolina
Medical Association 88: 303-306
214. McKinney P, Kellner C (1997) Multiple ECT late in the course of neuroleptic
malignant syndrome. Convulsive Therapy 13: 269-273
215. Medda P, Fornaro M, Fratta S, Callari A, Manzo V, Ciaponi B, Perugi G (2012)
A case of deep venous thrombosis following protracted catatonic immobility
recovered with electroconvulsive therapy: The relevance for an early intervention.
General Hospital Psychiatry 34: March
216. Memis D, Bayrak F, Tokatlioglu D, Gorman JM (2006) Neuroleptic malignant
syndrome: a case report. Journal of Psychiatric Practice 12: 259-262
217. Mihailescu C (2011) The neuroleptic malignant syndrome - a practical challenge
for every practitioner. Romanian Journal of Neurology/ Revista Romana de
Neurologie 10: 2011
16
218. Miller DD, Sharafuddin MJ, Kathol RG (1991) A case of clozapine-induced
neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52: 99-101
219. Mishra B, Mishra B, Sahoo S, Arora M, Khess CR (2007) Atypicality in
presentation of neuroleptic malignant syndrome caused by olanzapine. Indian
Journal of Medical Sciences 61: 570-573
220. Mitterschiffthaler G, Hackl JM, Neumann R (1989) Neuroleptic malignant
syndrome, a risk factor in malignant hyperthermia. [German]. Anaesthesist 38:
1989
221. Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K (1997)
Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype?
American Journal of Psychiatry 154: 882
222. Mohan KS, Gangadhar BN, Pradhan N, Channabasavanna SM (1985) The
description of the malignant neuroleptic syndrome. Nimhans Journal 3: 1985
223. Moltz DA, Coeytaux RR (1998) Case report: possible neuroleptic malignant
syndrome associated with olanzapine. Journal of Clinical Psychopharmacology
18: 485-486
224. Morrant JC (1984) A catatonic syndrome resulting in death. Canadian Journal of
Psychiatry - Revue Canadienne de Psychiatrie 29: 147-150
225. Morris E, Green D, Graudins A (2009) Neuroleptic malignant syndrome
developing after acute overdose with olanzapine and chlorpromazine. Journal of
Medical Toxicology: Official Journal of the American College of Medical
Toxicology 5: 27-31
226. Moysa GD, Anisete LV (1989) Neuroleptic malignant syndrome: successful
rechallenge with thioridazine. DICP 23: 712-713
227. Mueller PS, Vester JW, Fermaglich J (1983) Neuroleptic malignant syndrome.
Successful treatment with bromocriptine. Journal of the American Medical
Association 249: 1983
228. Mujica R, Weiden P (2001) Neuroleptic malignant syndrome after addition of
haloperidol to atypical antipsychotic. American Journal of Psychiatry 158: 650651
229. Mukai Y, Two A, Jean-baptiste M (2011) Chronic catatonia with obsessive
compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole,
fluvoxamine and neurosurgery. BMJ Case Reports
230. Murray S, Haller E (1995) Risperidone and NMS? Psychiatric Services 46: 951
17
231. Murty RG, Mistry SG, Chacko RC (2002) Neuroleptic Malignant Syndrome with
ziprasidone. Journal of Clinical Psychopharmacology 22: 624-626
232. Musselman ME, Browning LA, Parker J, Saely S (2011) Neuroleptic malignant
syndrome associated with the use of prochlorperazine in a patient with a recent
history of antipsychotic-induced neuroleptic malignant syndrome. Annals of
Pharmacotherapy 45: November
233. Najara JE, Enikeev ID (1995) Risperidone and neuroleptic malignant syndrome: a
case report. Journal of Clinical Psychiatry 56: 534-535
234. Najib J (1997) Neuroleptic malignant syndrome: A case report and review of
treatment. Hospital Pharmacy 32: April
235. Nakagawa M, Matsumura T, Kato D, Kishida I, Kawanishi C, Tamura K,
Hirayasu Y (2006) Neuroleptic malignant syndrome induced by perospirone.
International Journal of Neuropsychopharmacology 9: 635-636
236. Naramoto A, Koizumi N, Itoh N, Shigematsu H (1993) An autopsy case of
cerebellar degeneration following lithium intoxication with neuroleptic malignant
syndrome. Acta Pathologica Japonica 43: 1993
237. Nemets B, Geller V, Grisaru N, Belmaker RH (2000) Olanzapine treatment of
clozapine-induced NMS. Human Psychopharmacology 15: March
238. Nesemann ME, Michels JT, Pollei SR (1984) Neuroleptic malignant syndrome.
Wisconsin Medical Journal 83: 1984
239. Newman M, Adityanjee, Jampala C (1997) Atypical neuroleptic malignant
syndrome associated with risperidone treatment. American Journal of Psychiatry
154: 1475
240. Nielsen D, Aunsholt NA, Andersen PT (1987) Neuroleptic malignant syndrome
during perphenazine treatment. Pharmacology & Toxicology 60: 221-222
241. Nielsen D, Aunsholt NA, Andersen PT (1987) Neuroleptic malignant syndrome
during perphenazine treatment. Pharmacology & Toxicology 60: 221-222
242. Nielsen J, Bruhn AM (240) Atypical neuroleptic malignant syndrome caused by
olanzapine. Acta Psychiatrica Scandinavica 112: 238-240
243. Nierenberg D, Disch M, Manheimer E, Patterson J, Ross J, Silvestri G,
Summerhill E (1991) Facilitating prompt diagnosis and treatment of the
neuroleptic malignant syndrome. Clinical Pharmacology and Therapeutics 50:
1991
244. Nishioka Y, Miyazaki M, Kubo S, Ozono Y, Harada T, Kohno S (2002) Acute
renal failure in neuroleptic malignant syndrome. Renal Failure 24: 539-543
18
245. Nisijima K, Kusakabe Y, Ohtuka K, Ishiguro T (1998) Addition of carbamazepine
to long-term treatment with neuroleptics may induce neuroleptic malignant
syndrome. Biological Psychiatry 44: 930-931
246. Nisijima K, Ishiguro T (1999) Electroconvulsive therapy for the treatment of
neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
Journal of ECT 15: 158-163
247. Nolen WA, Zwaan WA (1990) Treatment of lethal catatonia with
electroconvulsive therapy and dantrolene sodium: a case report. Acta Psychiatrica
Scandinavica 82: 90-92
248. Nopoulos P, Flaum M, Miller DD (1990) Atypical neuroleptic malignant
syndrome (NMS) with an atypical neuroleptic: Clozapine-induced NMS without
rigidity. Annals of Clinical Psychiatry 2: 1990
249. Norris B, Angeles V, Eisenstein R, Seale JP (2006) Neuroleptic malignant
syndrome with delayed onset of fever following risperidone administration.
Annals of Pharmacotherapy 40: 2260-2264
250. Northoff G (2010) Options for the treatment of febrile catatonia. Journal of
Psychiatry & Neuroscience 35: E5-E6
251. Numata S, Kato O, Misawa H, Kanai T, Kasahara T, Ohmori T (2002) Treatment
of catatonia with olanzapine. German Journal of Psychiatry 5: 2002
252. O'Griofa FM, Voris JC (1991) Neuroleptic malignant syndrome associated with
carbamazepine. Southern Medical Journal 84: 1378-1380
253. O'Neill WM (1990) The neuroleptic malignant syndrome. Clinical Oncology
(Royal College of Radiologists) 2: 241-242
254. Obeid T, Rahim FMA, Daif KA (1988) The neuroleptic malignant syndrome.
Annals of Saudi Medicine 8: 1988
255. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H (2007) Neuroleptic
malignant syndrome induced by ziprasidone on the second day of treatment.
World Journal of Biological Psychiatry 8: 42-44
256. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H (2007) Neuroleptic
malignant syndrome induced by ziprasidone on the second day of treatment: A
case report [2]. World Journal of Biological Psychiatry 8: 2007
257. Padhy SK, Subodh BN, Bharadwaj R, Arun KK, Kumar S, Srivastava MK (2011)
Recurrent catatonia treated with lithium and carbamazepine: A series of 2 cases.
Primary Care Companion to the Journal of Clinical Psychiatry 13: 2011
19
258. Palermo GB (1991) Clinical considerations on neuroleptic malignant syndrome.
Journal of the Royal Society of Medicine 84: 1991
259. Panzer M, Tandon R, Greden JF (1990) Benzodiazepines and catatonia (I).
Biological Psychiatry 28: 1990
260. Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J (2009)
Catatonia as a risk factor for the development of neuroleptic malignant syndrome:
report of a case following treatment with clozapine. World Journal of Biological
Psychiatry 10: 70-73
261. Parker WA (1987) Neuroleptic malignant syndrome. Critical Care Nurse 7: 40-48
262. Parry AK, Ormerod LP, Hamlin GW, Saleem PT (1994) Recurrent sinus arrest in
association with neuroleptic malignant syndrome. British Journal of Psychiatry
164: 689-691
263. Pasa S, Sayhan MB, Boyraz T, Urakci Z, Altintas A (2008) A Case of neuroleptic
malignant syndrome accompanied to an atypical antipsychotic agent: risperidone.
Neurotoxicology 29: 750-751
264. Patel MK, Brunetti L (2010) Neuroleptic malignant syndrome secondary to
aripiprazole initiation in a clozapine-intolerant patient. American Journal of
Health-System Pharmacy 67: 1254-1259
265. Patel U, Agrawal M, Krishnan P, Niranjan S (2002) Neuroleptic malignant
syndrome presenting as pulmonary edema and severe bronchorrhea. Journal of the
National Medical Association 94: 279-282
266. Patkar AA, Shah LP (1991) Neuroleptic malignant syndrome (a case report).
Journal of Postgraduate Medicine 37: 168-170
267. Paul M, Michael SG, John S, Lenox RJ (2012) An atypical presentation of
neuroleptic malignant syndrome: Diagnostic dilemma in a critical care setting.
Respiratory Care 57: February
268. Peiris DT, Kuruppuarachchi K, Weerasena LP, Seneviratne SL, Tilakaratna YT,
De Silva HJ, Wijesiriwardena B (2000) Neuroleptic malignant syndrome without
fever: a report of three cases. Journal of Neurology, Neurosurgery & Psychiatry
69: 277-278
269. Pennati A, Sacchetti E, Calzeroni A (1991) Dantrolene in lethal catatonia.
American Journal of Psychiatry 148: 268
270. Pereira YDS, Srivastava A, Cuncoliencar BS, Naik N (2010) Resolution of
symptoms in neuroleptic malignant syndrome. Indian Journal of Psychiatry 52:
July-September
20
271. Perera HV (1986) Neuroleptic malignant syndrome. Ceylon Medical Journal 31:
197-198
272. Perez de los Cobos JC, O'Neill A, Lopez-Ibor JJ, Jr. (1992) Galactorrhea in the
neuroleptic malignant syndrome. European Neuropsychopharmacology 2: 87-89
273. Peschel O, Kurtz G, Muller-Felber W, Modell S (1994) [Rhabdomyolysis in
neuroleptic therapy: an abortive malignant neuroleptic syndrome?]. [German].
Nervenarzt 65: 718-721
274. Pesola GR, Quinto C (1996) Prochlorperazine-induced neuroleptic malignant
syndrome. Journal of Emergency Medicine 14: 727-729
275. Petursson H (1976) Lithium treatment of a patient with periodic catatonia. Acta
Psychiatrica Scandinavica 54: 248-253
276. Pirovino M, Meier J, Meyer M (1984) Neuroleptic malignant syndrome.
[German]. Deutsche Medizinische Wochenschrift 109: 1984
277. Plesnicar BK, But MF, Zalar B (2004) Malignant catatonia/neuroleptic malignant
syndrome or how to change the view on ECT [1]. Journal of ECT 20: 2004
278. Poyurousky M, Bergman J, Weizman A (1997) Risperidone in the treatment of
catatonia in a schizophrenic patient. Israel Journal of Psychiatry & Related
Sciences 34: 323-324
279. Price DK, Turnbull GJ, Gregory RP, Stevens DG (1989) Neuroleptic malignant
syndrome in a case of post-partum psychosis. British Journal of Psychiatry 155:
849-852
280. Price WA, Giannini AJ (1983) A paradoxical response to chlorpromazine. A
possible variant of the neuroleptic malignant syndrome. Journal of Clinical
Pharmacology 23: 1983
281. Quarles E, Norton JW (1999) The clinical presentation of neuroleptic malignant
syndrome. Hospital Pharmacy 34: March
282. Rai S, Arun P (2007) Lithium-induced neuroleptic malignant syndrome: A case
report. Hong Kong Journal of Psychiatry 17: September
283. Raja M, Altavista MC, Cavallari S, Lubich L (1994) Neuroleptic malignant
syndrome and catatonia. A report of three cases. European Archives of Psychiatry
& Clinical Neuroscience 243: 299-303
284. Raja M, Miti G (1995) Neuroleptic malignant syndrome [1]. Neuropsychiatry,
Neuropsychology and Behavioral Neurology 8: 1995
21
285. Rankel HW, Rankel LE (1988) Carbamazepine in the treatment of catatonia.
American Journal of Psychiatry 145: 361-362
286. Ray JG (1997) Neuroleptic malignant syndrome associated with severe
thrombocytopenia. Journal of Internal Medicine 241: 1997
287. Rechlin T, Hilz MJ, Claus D (1991) Successful treatment of neuroleptic
malignant syndrome with dantrolene sodium in the neurological intensive care
unit. [German]. Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie
26: 1991
288. Reddig S, Minnema AM, Tandon R (1993) Neuroleptic malignant syndrome and
clozapine. Annals of Clinical Psychiatry 5: 25-27
289. Reeves RR, Mack JE, Torres RA (2001) Neuroleptic malignant syndrome during
a change from haloperidol to risperidone. Annals of Pharmacotherapy 35: 698701
290. Reeves RR, Torres RA, Liberto V, Hart RH (2002) Atypical neuroleptic
malignant syndrome associated with olanzapine. Pharmacotherapy:The Journal of
Human Pharmacology & Drug Therapy 22: 641-644
291. Reinish LW, Remick RA (1988) Neuroleptic malignant syndrome: A case report.
Canadian Family Physician 34: 1988
292. Remy K, Slater J, Feuer P (2009) An interesting case of emergent
electroconvulsive therapy for acute catatonia. Critical Care Medicine Conference:
December
293. Renfordt E, Wardin B (1985) ECT and Dantrolen in the treatment of acute febrile
catatonia: A case report. [German]. Nervenarzt 56: 1985
294. Rimon R, Viukari M (1978) Neuroleptic malignant syndrome: an unusual side
effect of depot fluphenazine. Psychiatria Fennica Vol.: 1978
295. Rock W, Elias M, Lev A, Saliba WR (2009) Haloperidol-induced neuroleptic
malignant syndrome complicated by hyperosmolar hyperglycemic state.
American Journal of Emergency Medicine 27: 1018-3
296. Rodriguez ME, Luquin MR, Lera G, Delgado G, Salazar JM, Obeso JA (1990)
Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion.
Movement Disorders 5: 170-172
297. Rodriguez OP, Dowell MS (2006) A case report of neuroleptic malignant
syndrome without fever in a patient given aripiprazole. Journal - Oklahoma State
Medical Association 99: 435-438
22
298. Rosebush PI, MacQueen GM, Mazurek MF (1999) Catatonia following
gabapentin withdrawal [5]. Journal of Clinical Psychopharmacology 19: 1999
299. Rothke S, Bush D (1986) Neuropsychological sequelae of neuroleptic malignant
syndrome. Biological Psychiatry 21: 1986
300. Roy N, Diaz PL, Howard J (2000) Neuroleptic malignant syndrome associated
with quetiapine. Canadian Journal of Hospital Pharmacy 53: 2000
301. Rummans TA, Bassingthwaighte ME (1991) Severe medical and neurologic
complications associated with near-lethal catatonic treated with electroconvulsive
therapy. Convulsive Therapy 7: 1991
302. Sager SM (1991) Neuroleptic malignant syndrome: A diagnostic dilemma.
Journal of the Royal Society of Medicine 84: 1991
303. Sato T, Hara T, Takeichi M (1992) A case of neuroleptic malignant syndrome
with a history of general anesthesia. Human Psychopharmacology 7: 1992
304. Saunders BP, Trewby PN (1993) The neuroleptic malignant syndrome: A missed
diagnosis? British Journal of Clinical Practice 47: 1993
305. Schrader G, Wong C, Russell R, Goldney RD (1981) The neuroleptic malignant
syndrome. Medical Journal of Australia 2: 494
306. Schulte-Sasse U, Komar K, Eberlein HJ (1985) [Dantrolene in the treatment of
life-threatening psychiatric disease pictures. A contribution to the therapy of the
malignant neuroleptic syndrome and acute febrile catatonia]. [German]. Deutsche
Medizinische Wochenschrift 110: 457-461
307. Schulz P, Dick P (722) Therapeutic rounds: neuroleptic malignant syndrome.
Clinical Therapeutics 8: 605-606
308. Sczesni B, Bittkau S, Von BF, Von SJ, Suchy I, Przuntek H (1991) Intravenous
lisuride in the treatment of the neuroleptic malignant syndrome. Journal of
Clinical Psychopharmacology 11: 1991
309. Segal J, Isaacs MD, Berk M (2001) Neuroleptic malignant syndrome: Possible
induction by olanzapine in a case with relapsing catatonia. International Journal of
Psychiatry in Clinical Practice 5: 2001
310. Seitz DP (2005) Diagnostic uncertainty in a case of neuroleptic malignant
syndrome. Canadian Journal of Emergency Medicine 7: July
311. Shafer WH, Furlan AJ (1986) Neuroleptic malignant syndrome. An unusual cause
of fever. Cleveland Clinic Quarterly 53: 1986
312. Shah AK (1991) Catatonia and NMS [14]. British Journal of Psychiatry 159: 1991
23
313. Shams J, Rahmani B, Asefi F, Daneshfar S (2010) Catatonia development in a
schizoaffective patient following electroconvulsive therapy. Iranian Journal of
Psychiatry and Behavioral Sciences 4: Autumn-Winter
314. Shetty S, Vize C (2010) An unusual case of neuroleptic malignant syndrome.
Journal of Neuropsychiatry and Clinical Neurosciences 22: Winter
315. Shinozaki T, Nishimura H, Kasahara H, Nakabayashi H, Watanabe R, Ushijima S
(1994) A case of psychotic disorder complicated by nemaline myopathy with
neuroleptic malignant syndrome. Jikeikai Medical Journal 41: 1994
316. Shoop SA, Cernek PK (1997) Carbidopa/levodopa in the treatment of neuroleptic
malignant syndrome [2]. Annals of Pharmacotherapy 31: 1997
317. Shukla I, Singh O, Rehman N (2006) Neuroleptic malignant syndrome in critical
care unit. Indian Journal of Critical Care Medicine 10: January
318. Shuster J (1997) Risperidone and neuroleptic malignant syndrome. Recognizing a
potentially fatal condition. Nursing 27: 68
319. Sierra-Biddle D, Herran A, ez-Aja S, Gonzalez-Mata JM, Vidal E, ez-Manrique
F, Vazquez-Barquero JL (2000) Neuroleptic malignant syndrome and olanzapine
[2]. Journal of Clinical Psychopharmacology 20: 2000
320. Singh N, Wise TN (2010) Neuroleptic malignant syndrome after exposure to
asenapine: A case report. Primary Care Companion to the Journal of Clinical
Psychiatry 12: 2010
321. Singh SP, Giridhar C, Avasthi A (1989) Neuroleptic malignant syndrome with
trifluperidol. British Journal of Psychiatry 155: 561-563
322. Singh SP, Giridhar C, Avasthi A (1989) Neuroleptic malignant syndrome with
trifluperidol. British Journal of Psychiatry 155: 561-563
323. Smith M, Lebegue B (1991) Lorazepam in the treatment of catatonia. American
Journal of Psychiatry 148: 1265
324. Sokoro AA, Zivot J, Ariano RE (2011) Neuroleptic malignant syndrome versus
serotonin syndrome: the search for a diagnostic tool. Annals of Pharmacotherapy
45: e50
325. Solomons K (2002) Quetiapine and neuroleptic malignant syndrome. Canadian
Journal of Psychiatry - Revue Canadienne de Psychiatrie 47: 791
326. Solomons K (2002) Quetiapine and neuroleptic malignant syndrome. Canadian
Journal of Psychiatry - Revue Canadienne de Psychiatrie 47: 791
24
327. Sovner RD, McHugh PR (1974) Lithium in the treatment of periodic catatonia: a
case report. Journal of Nervous & Mental Disease 158: 214-221
328. Spiegel DR, Varnell C (2011) A case of catatonia due to posterior reversible
encephalopathy syndrome treated successfully with antihypertensives and
adjunctive olanzapine. General Hospital Psychiatry 33: May-June
329. Spivak B, Weizman A, Wolovick L, Hermesh H, Tyano S, Munitz H (1990)
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Acta Psychiatrica Scandinavica 81: 168-169
330. Spivak M, Adams B, Crockford D (2003) Atypical neuroleptic malignant
syndrome with clozapine and subsequent haloperidol treatment. Canadian Journal
of Psychiatry - Revue Canadienne de Psychiatrie 48: 66
331. Srephichit S, Sanchez R, Bourgeois JA (2006) Neuroleptic malignant syndrome
and aripiprazole in an antipsychotic-naive patient. Journal of Clinical
Psychopharmacology 26: 94-95
332. Srinivasan AV, Murugappan M, Krishnamurthy SG, Sayeed ZA (1990)
Neuroleptic malignant syndrome. Journal of Neurology, Neurosurgery &
Psychiatry 53: 514-516
333. Srivastava A, Borkar HA, Chandak S (2009) Olanzapine-induced neuroleptic
malignant syndrome in a patient with paranoid schizophrenia. Psychiatry &
Clinical Neurosciences 63: 119-121
334. Stanfield SC, Privette T (2000) Neuroleptic malignant syndrome associated with
olanzapine therapy: a case report. Journal of Emergency Medicine 19: 355-357
335. Staud L, Pflug B (1992) [Neuroleptic malignant syndrome--a case report on
diagnosis, differential diagnosis and therapy of a life threatening complication of
treatment with neuroleptics]. [German]. Psychiatrische Praxis 19: 114-118
336. Stevens DL, Lee MR, Padua Y (2008) Olanzapine-associated neuroleptic
malignant syndrome in a patient receiving concomitant rivastigmine therapy.
Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy 28: 403405
337. Stoner SC, Berry A (2010) Suspected neuroleptic malignant syndrome during
quetiapine-clozapine cross-titration. Journal of Pharmacy Practice 23: 69-73
338. Storm C, Gebker R, Kruger A, Nibbe L, Schefold JC, Martens F, Hasper D (2009)
A rare case of neuroleptic malignant syndrome presenting with serious
hyperthermia treated with a non-invasive cooling device: A case report. Journal of
Medical Case Reports 3:
25
339. Straker M (1986) Neuroleptic malignant syndrome: fatalities associated with
neuroleptic use and schizophrenia. Psychiatric Journal of the University of Ottawa
11: 28-30
340. Strawn JR, Keck PE, Jr. (2006) Early bicarbonate loading and dantroline for
ziprasidone/haloperidol-induced neuroleptic malignant syndrome. Journal of
Clinical Psychiatry 67: 677
341. Sugden SG, Bourgeois JA, Kile SJ, Hilty DM (2004) Neuroleptic malignant
syndrome with dermatologic complications. Journal of Clinical
Psychopharmacology 24: 676-678
342. Supe S, Matijevic V, Kondic L, Alvir D (2006) Series of seizures as a sign of
development of recurrent malignant neuroleptic syndrome - a case report.
Psychiatria Danubina 18: 97-101
343. Suzuki K, Shindo T, Katsura M, Takamatsu K, Ebina Y, Takano T, Awata S,
Matsuoka H (2007) Resolution of catatonia by successful seizure induction via
electroconvulsive therapy with electrodes applied bilaterally to the
parietotemporal region. Journal of ECT 23: 103-105
344. Tadke RR, Suryavanshi P (2006) Use of intravenous valproate in a patient with
neuroleptic malignant syndrome. Journal of Neuropsychiatry & Clinical
Neurosciences 18: 131-132
345. Takizawa D, Nishikawa K, Hiraoka H, Hinohara H, Saito S, Goto F, Kunimoto F
(2004) Successful management of a patient with neuroleptic malignant syndrome
associated with marked elevation of serum creatine kinase. Journal of Anesthesia
18: 2004
346. Tanaka O, Otani K, Kondo T, Knaeko S, Fukushima Y (1993) Paralytic ileus as a
prodromal symptom of the neuroleptic malignant syndrome. Human
Psychopharmacology 8: 1993
347. Tanii H, Saka K, Inoue K, Okada M (2010) Neuroleptic malignant syndrome
following levomepromazine discontinuation. Journal of Neuropsychiatry &
Clinical Neurosciences 22: E16
348. Teng P-R, Lane H-Y (2011) Emergence of neuroleptic malignant syndrome while
switching between risperidone and paliperidone. Journal of Neuropsychiatry and
Clinical Neurosciences 23: 2011
349. Thomas P, Maron M, Rascle C, Cottencin O, Vaiva G, Goudemand M (1998)
Carbamazepine in the treatment of neuroleptic malignant syndrome. Biological
Psychiatry 43: 303-305
350. Thomas RB (1987) The neuroleptic malignant syndrome. Case report. Wisconsin
Medical Journal 86: 1987
26
351. Tian CS, Tsoi WF (1988) Neuroleptic malignant syndrome--report of a case.
Singapore Medical Journal 29: 80-82
352. Tofler IT, Ahmed B (2003) Atypical (olanzapine) plus conventional
(fluphenazine) neuroleptic treatment associated with the neuroleptic malignant
syndrome. Journal of Clinical Psychopharmacology 23: 672-674
353. Tollefson G (1982) A case of neuroleptic malignant syndrome: in vitro muscle
comparison with malignant hyperthermia. Journal of Clinical
Psychopharmacology 2: 266-270
354. Topka H, Buchkremer G (1996) Lethal catatonia, malignant neuroleptic syndrome
and myositis ossificans. [German]. Nervenarzt 67: 1996
355. Trayer JS, Fidler DC (1998) Neuroleptic malignant syndrome related to use of
clozapine. Journal of the American Osteopathic Association 98: 168-169
356. Trollor JN, Sachdev PS (1999) Electroconvulsive treatment of neuroleptic
malignant syndrome: A review and report of cases. Australian and New Zealand
Journal of Psychiatry 33: October
357. Truong DD, Sczesni B, Fahn S, Gross J, Donovan K, van BA, Wiley MK (1988)
[Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia).
4 different cases]. [German]. Nervenarzt 59: 103-109
358. Tsai G, Crisostomo G, Rosenblatt ML, Stern TA (1995) Neuroleptic malignant
syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 7:
91-95
359. Tsai JH, Yang P, Yen JY, Chen CC, Yang MJ (2005) Zotepine-induced catatonia
as a precursor in the progression to neuroleptic malignant syndrome.
Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy 25:
1156-1159
360. Tsai MC, Huang TL (2010) Severe neuroleptic malignant syndrome: successful
treatment with high-dose lorazepam and diazepam: a case report. Chang Gung
Medical Journal 33: 576-580
361. Tu MC, Hsiao CC (2011) Amisulpride and neuroleptic malignant syndrome.
Chang Gung Medical Journal 34: 536-540
362. Unaldi M, Sayhan MB, Sogut O, Demirhan R, Guzel B (2010) Neuroleptic
malignant syndrome after the addition of lithium to risperidone treatment: A case
report and review of the literature. Hong Kong Journal of Emergency Medicine
17: July
27
363. Valevski A, Loebl T, Keren T, Bodinger L, Weizman A (2001) Response of
catatonia to risperidone: two case reports. Clinical Neuropharmacology 24: 228231
364. Vancaester E, Santens P (2007) Catatonia and neuroleptic malignant syndrome:
two sides of a coin? Acta Neurologica Belgica 107: 47-50
365. Varoglu AO, Ates O, Gundogdu OL, Aksoy A, Deniz O (2009) Zuclopenthixolinduced neuroleptic malignant syndrome presenting as fever of unknown origin,
hyperglycaemia and acute myocardial infarction in a 60-year-old man. World
Journal of Biological Psychiatry 10: t-7
366. Vattakatuchery JJ, Chinnaswamy S, Tranter R (2008) Combination of
electroconvulsive therapy and clozapine in the treatment of malignant catatonia:
A case report. Hong Kong Journal of Psychiatry 18: March
367. Vedie C, Poinso F, Hemmi F, Rivet B (2000) Major symptoms and differential
diagnosis of neuroleptic malignant syndrome: Three case reports. European
Psychiatry 15: 2000
368. Vetter P, Proppe D, Hoppe-Seyler S (1991) [Neuroleptic malignant syndrome
with clozapine monotherapy and benign hyperthermia after resolving neuroleptic
malignant syndrome with clozapine. Two case reports]. [German]. Nervenarzt 62:
55-57
369. Voros V, Kovacs A, Herold R, Osvath P, Simon M, Fekete S, Tenyi T (2009)
Effectiveness of intramuscular aripiprazole injection in patients with catatonia:
Report on three cases. Pharmacopsychiatry 42: November
370. Wachtel LE, Griffin M, Reti IM (2010) Electroconvulsive therapy in a man with
autism experiencing severe depression, catatonia, and self-injury. Journal of ECT
26: March
371. Wager O, Hell D (1988) Neuroleptic malignant syndrome: literature and a case.
[German]. Schweizerische Medizinische Wochenschrift 118: 1988
372. Wald D, Lerner J (1978) Lithium in the treatment of periodic catatonia: A case
report. American Journal of Psychiatry 135: 1978
373. Wang HC, Hsieh Y (2001) Treatment of neuroleptic malignant syndrome with
subcutaneous apomorphine monotherapy. Movement Disorders 16: 765-767
374. Wee JCP, Wong E, Annathurai A (2010) A case of risperidone-associated
neuroleptic malignant syndrome in a patient receiving long-term haloperidol
treatment. Hong Kong Journal of Emergency Medicine 17: July
375. Weinberg S, Twersky RS (1983) Neuroleptic malignant syndrome. Anesthesia &
Analgesia 62: 848-850
28
376. Weinberger DR, Kelly MJ (1977) Catatonia and malignant syndrome: a possible
complication of neuroleptic administration. Report of a case involving
haloperidol. Journal of Nervous & Mental Disease 165: 263-268
377. Weller M, Kornhuber J, Beckmann H (1992) Electroconvulsive therapy for lethal
catatonia associated with toxic epidermal necrolysis (Lyell syndrome). [German].
Nervenarzt 63: 1992
378. White DA (1992) Catatonia and the neuroleptic malignant syndrome--a single
entity? British Journal of Psychiatry 161: 558-560
379. Williams K, MacPherson R (1997) Reintroduction of antipsychotics in a patient
with clozapine induced neuroleptic malignant syndrome. Irish Journal of
Psychological Medicine 14: 1997
380. Wong MM (1996) Neuroleptic malignant syndrome: two cases without muscle
rigidity. Australian & New Zealand Journal of Psychiatry 30: 415-418
381. Woodcock R (1986) Neuroleptic malignant syndrome. Journal of Emergency
Nursing 12: 305-307
382. Xerri B, Lefevre MM, Paolaggi JB (1994) Neuroleptic malignant syndrome
induced by a single injection of tiapride [4]. Revue du Rhumatisme (English
Edition) 61: 1994
383. Yaci H, Akbay OA, Mayda DF, Uz Y, Koca E, Yeni ER (2011) Neuroleptic
malignant syndrome: A case report. European Journal of Neurology Conference:
September
384. Yamawaki S, Yanagawa K, Morio M, Mori K (1986) Possible central effect of
dantrolene sodium in neuroleptic malignant syndrome. Journal of Clinical
Psychopharmacology 6: 378-379
385. Yasugi S, Garg V, Been G, Magoulas P (2010) Neuroleptic malignant syndrome.
Australian & New Zealand Journal of Psychiatry 44: 584
386. Yildiz A, Alkin T, Ozerdem A, Sagduyu K, Demopulos CM (2003) Neuroleptic
malignant syndrome: a case that may shed new light into the etiology and
treatment. Australian & New Zealand Journal of Psychiatry 37: 493-494
29